Clinical Trials
59 trialsREVIVE
Asan Medical Center
CCGLC-011
Tongji Hospital
FLEX-HCC
CHA University
TREMENDOUS-2
AstraZeneca
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Peking Union Medical College Hospital
GDFATHERHCC01
CatalYm GmbH
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Emory University
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
SLIDE-HCC
Canadian Cancer Trials Group
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
BLP-HCC
Fudan University
LENVABLA
Assistance Publique - Hôpitaux de Paris
FRONT-1
Guangxi Medical University
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Academic and Community Cancer Research United
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
KEYVIBE-005
Merck Sharp & Dohme LLC
LIVIGNO-1
AbbVie
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
LEAF-01
Fudan University
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
Akeso
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Tongji Hospital
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
Second Affiliated Hospital of Guangzhou Medical University
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib
Northern Jiangsu People's Hospital
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
BeiGene
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Lion TCR Pte. Ltd.
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
Zhejiang Cancer Hospital
PRIMER-1
University College, London
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
Nanfang Hospital, Southern Medical University
Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
Asan Medical Center
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Hunan Cancer Hospital
HSBRT2401
Sun Yat-sen University
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma
The First Affiliated Hospital of Bengbu Medical University
HAI-TL
Eastern Hepatobiliary Surgery Hospital
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
Second Affiliated Hospital of Guangzhou Medical University
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
Guangdong Provincial People's Hospital
CASTLE-10
Fudan University
Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Zhejiang Cancer Hospital
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
Sun Yat-sen University
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma
Sun Yat-sen University
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
The Methodist Hospital Research Institute
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
PLATIC
Sun Yat-sen University
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
Peking University Cancer Hospital & Institute
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
Sun Yat-sen University